title: [Capecitabine-induced subacute cutaneous lupus: a case report].
abstract: BACKGROUND
  More than 100 drugs have been registered as inducing subacute cutaneous lupus erythematosus (SCLE). Recently, some types of chemotherapy have also been incriminated. If SCLE develops in a setting of neoplasia, two possibilities should be considered: it is either a paraneoplastic syndrome or it is caused by the chemotherapy, thus calling for important decisions on the benefit/risk of stopping potentially effective medication. We report a case of SCLE induced by Xeloda (capecitabine).
  
  
  METHODS
  A 50-year-old female patient consulted with an annular erythematosquamous and pruriginous eruption, predominantly on areas of the body exposed to sunlight, occurring 4 months after the initiation of capecitabine for advanced colon cancer. She had presented systemic lupus erythematosus (SLE) for many years, which was not treated, was not progressive and had no cutaneous manifestations. The appearance of the cutaneous lesions, positivity for anti-SSA antibodies and the histological aspect led to diagnosis of SCLE. The lesions were resistant to treatment with hydroxychloroquine and systemic corticosteroids, but disappeared after discontinuation of capecitabine, suggesting chemotherapy-induced SCLE.
  
  
  CONCLUSIONS
  Some types of chemotherapy such as capecitabine may reveal or induce SCLE lesions, whether or not there is a previous history of SLE. Cases of chemotherapy-induced cutaneous lupus reported to the French pharmacovigilance agency are rare, but this side effect must be recognised due to the constantly rising use of this type of anticancer agent.
authors.affiliation: Service de dermatologie, CHU La Timone, 13005 Marseille, France; Service de médecine interne, centre de compétence PACA Ouest pour la prise en charge des pathologies auto-immunes systémiques, CHU de la Conception, 147, boulevard Baille, 13005 Marseille, France.
authors.forename: J
authors.initials: J
authors.lastname: Fongue
authors.affiliation: Service de médecine interne, centre de compétence PACA Ouest pour la prise en charge des pathologies auto-immunes systémiques, CHU de la Conception, 147, boulevard Baille, 13005 Marseille, France.
authors.forename: B
authors.initials: B
authors.lastname: Meunier
authors.affiliation: Cabinet de dermatologie, 47B, avenue Maréchal-Foch, 83390 Cuers, France.
authors.forename: D
authors.initials: D
authors.lastname: Lardet
authors.affiliation: Service de médecine interne, centre de compétence PACA Ouest pour la prise en charge des pathologies auto-immunes systémiques, CHU de la Conception, 147, boulevard Baille, 13005 Marseille, France.
authors.forename: M-P
authors.initials: MP
authors.lastname: Dicostanzo
authors.affiliation: Pharmacovigilance, hôpital Salvator, 13009 Marseille, France.
authors.forename: F
authors.initials: F
authors.lastname: Rouby
authors.affiliation: Laboratoire d'anatomopathologie, 219, rue Revel, 83000 Toulon, France.
authors.forename: J-P
authors.initials: JP
authors.lastname: Terrier
authors.affiliation: Service de médecine interne, centre de compétence PACA Ouest pour la prise en charge des pathologies auto-immunes systémiques, CHU de la Conception, 147, boulevard Baille, 13005 Marseille, France.
authors.forename: J-R
authors.initials: JR
authors.lastname: Harlé
authors.affiliation: Service de dermatologie, CHU La Timone, 13005 Marseille, France.
authors.forename: M-A
authors.initials: MA
authors.lastname: Richard
authors.affiliation: Service de médecine interne, centre de compétence PACA Ouest pour la prise en charge des pathologies auto-immunes systémiques, CHU de la Conception, 147, boulevard Baille, 13005 Marseille, France. Electronic address: laurent.chiche@ap-hm.fr.
authors.forename: L
authors.initials: L
authors.lastname: Chiche
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D000069287:Capecitabine; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005602:France; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000175:diagnosis; D008875:Middle Aged
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil
keywords: Capecitabine; Capécitabine; Chemotherapy; Chimiothérapie; Induced cutaneous lupus erythematosus; Lupus cutané induit; Lupus érythémateux subaigu; Subacute cutaneous lupus erythematosus